Scholarlink

<p>CHRONOS is a multicenter, retrospective, cohort study involving acute graft-versus-host disease (aGvHD) adult patients with gastrointestinal (GI) symptoms, steroid- and ruxolitinib refractory, who initiated third-line therapy between 30 May 2019 and 30 September 2024. Primary endpoints were all-organ overall response rate (ORR) and GI-specific ORR (GI-ORR) around 28 days after treatment initiation. Secondary endpoints included duration of response, real-world progression-free survival (rwPFS) of underlying malignancy, and overall survival (OS). Fifty-nine patients from 16 sites in Europe were included. On Day 28, ORR was 36% (95% CI: 24–49%), GI-ORR was 37% (95% CI: 25–51%); 29% (95% CI: 11–49%) of responders lost response within 30 days, and 52% (95% CI: 29–72%) within 90 days. Median rwPFS and median OS were both 86 days (95% CI: 54–128 days). Median OS was higher in responders than in non-responders (186 versus 45 days). Over the 12-month follow-up period, 41 patients died, mainly due to aGvHD progression (<i>n</i> = 25), and infectious complications (<i>n</i> = 9). Within 3 months, Grade ≥ 2 infectious events occurred in 51% of patients; Grade 3–4 thrombocytopenia and neutropenia in 64% and 32%, respectively. These findings demonstrate limited effectiveness of third-line therapy in this cohort of steroid- and ruxolitinib-refractory aGvHD patients with GI symptoms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure

  • 期刊论文

  • 发表日期：

    2026年3月28日

查看全文
  • Johannes Clausen,
  • José Antonio Pérez Simón,
  • Martin Carré,
  • Cristina Castilla-Llorente,
  • David Michonneau,
  • Alexander Schauwvlieghe,
  • Pedro Asensi Cantó,
  • Sylvie François,
  • Ludovic Gabellier,
  • Lucía López Corral,
  • Ana Benzaquén,
  • Hélène Labussière-Wallet,
  • Jérome Cornillon,
  • Raynier Devillier,
  • Anne Huynh,
  • Pascal Turlure,
  • Anna Bauhofer,
  • Hervé Jullien de Pommerol,
  • Marion Bruelle,
  • Imi Faghmous,
  • Behzad Kharabi Masouleh,
  • Emilie Plantamura,
  • Florent Malard,
  • Mohamad Mohty

摘要

CHRONOS is a multicenter, retrospective, cohort study involving acute graft-versus-host disease (aGvHD) adult patients with gastrointestinal (GI) symptoms, steroid- and ruxolitinib refractory, who initiated third-line therapy between 30 May 2019 and 30 September 2024. Primary endpoints were all-organ overall response rate (ORR) and GI-specific ORR (GI-ORR) around 28 days after treatment initiation. Secondary endpoints included duration of response, real-world progression-free survival (rwPFS) of underlying malignancy, and overall survival (OS). Fifty-nine patients from 16 sites in Europe were included. On Day 28, ORR was 36% (95% CI: 24–49%), GI-ORR was 37% (95% CI: 25–51%); 29% (95% CI: 11–49%) of responders lost response within 30 days, and 52% (95% CI: 29–72%) within 90 days. Median rwPFS and median OS were both 86 days (95% CI: 54–128 days). Median OS was higher in responders than in non-responders (186 versus 45 days). Over the 12-month follow-up period, 41 patients died, mainly due to aGvHD progression (n = 25), and infectious complications (n = 9). Within 3 months, Grade ≥ 2 infectious events occurred in 51% of patients; Grade 3–4 thrombocytopenia and neutropenia in 64% and 32%, respectively. These findings demonstrate limited effectiveness of third-line therapy in this cohort of steroid- and ruxolitinib-refractory aGvHD patients with GI symptoms.